| Patient | Wilma Mankiller |
|---|---|
| Date of birth | 1991-11-18 |
| Identifiers | MRN HR-ML052-SYN; SSN (made up) 000-52-4183 |
| Document date | 2026-03-09 |
| Author | Rena Hawkfeather-Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Woman of 34 with six weeks of fluctuating ptosis, diplopia and fatigable weakness of the arms, neck, chewing and voice, while recovering from a severe car crash last year: suspected generalized myasthenia gravis. Please confirm the diagnosis and advise on treatment, thymectomy and safety. [S]
Urgency: Urgent, within two weeks. [S]
Questions for the consultant:
Cherokee Nation citizen living in rural Adair County, about an hour's drive from this clinic; works for the Cherokee Nation. Head-on car crash last year with fractures of both legs, ribs and face and many operations; walks independently, with a cane on rough ground. Hereditary polycystic kidney disease, as she has described it, with normal kidney function. Examination: left-predominant ptosis after 30 seconds of upgaze, improved by 3 mm after a two-minute ice pack; diplopia on sustained lateral gaze; neck flexion 4 of 5; deltoids fatigue after 30 seconds; nasal voice after counting to 30; reflexes and sensation normal. FVC 3.30 L, negative inspiratory force -70 cm H2O, single-breath count 32. Blood count, chemistry and TSH normal; creatinine 0.78 mg/dL, eGFR 102, urine albumin 14 mg/g; hemoglobin A1c 5.3 percent. PHQ-9 score 7. Acetylcholine receptor antibodies sent; chest CT with contrast and kidney ultrasound booked. Pyridostigmine 30 mg three times daily started as a trial. No other regular medicines except acetaminophen. She would like blood tests near home where possible and her own Cherokee medicine respected [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
8 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating | One tablet three times daily | Oral route | 2026-03-09 to 2026-03-23 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain | One or two tablets up to three times daily as needed | Oral route | 2025-09-15 | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | active | confirmed | H53.2 | S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis. |
| Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed | Q61.2 | S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic. |
| Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed | Z87.81 | S — The crash, the operations and the injuries are documented (D); the current function is synthetic. |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1979 (1978 in one account) | Near-fatal head-on car crash with about 17 operations, with fractures of the legs, ribs and face | D (CLM-0005) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-09 | Body height | 163 | cm | S |
| 2026-03-09 | Body weight | 61.8 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 23.3 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 78 | /min | S |
| 2026-03-09 | Respiratory rate | 16 | /min | S |
| 2026-03-09 | Body temperature | 36.7 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-03-09 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-09 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-09 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-09 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-45 U/L | Normal | S |
| 2026-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 8-43 U/L | Normal | S |
| 2026-03-09 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-03-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.3 | % | <=5.6% | Normal | S |
| 2026-03-09 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g | Below 30 mg/g is normal (A1) | Normal | S |
| 2026-03-09 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 31 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-03-09 | Forced vital capacity [Volume] Respiratory system | 3.3 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S |